Werewolf Therapeutics (United States)

Alternate names: Werewolf Therapeutics, Werewolf Therapeutics Inc

ROR: 01wrd9933

OpenAlex ID: I4405263496

Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression

2022 · Christopher J. Nirschl, Heather R. Brodkin, et al. · Cancer Immunology Research · 66

Progressively Enhancing Stemness of Adoptively Transferred T Cells with PI3Kδ Blockade Improves Metabolism and Antitumor Immunity

2023 · Guillermo O. Rangel Rivera, Connor J. Dwyer, et al. · Cancer Research · 33

PDF

mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity

2023 · Christopher J. Nirschl, Heather R. Brodkin, et al. · Cancer Immunology Research · 24

PDF

Conditionally Activated IL-12 or IFNα Indukine™ Molecules Inhibit Syngeneic Lymphoma Tumor Growth in Mice, Induce Anti-Tumor Immune Responses and Are Tolerated in Non-Human Primates

2021 · Philipp Steiner, Heather Brodkin, et al. · Blood · 11

A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab.

2024 · Justin C Moser, Mateusz Opyrchal, et al. · Journal of Clinical Oncology · 6

715 WTX-330 is an IL-12 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models

2021 · Kristin Morris, Heather Brodkin, et al. · Journal for ImmunoTherapy of Cancer · 4

PDF

Abstract 1716: WTX-330, a conditionally activated IL-12 INDUKINE, releases IL-12 selectively in the tumor microenvironment to activate anti-tumor immune responses and induce regressions in mouse tumor models

2021 · Philipp Steiner, Heather Brodkin, et al. · Cancer Research · 4

737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors

2023 · Justin C Moser, Mateusz Opyrchal, et al. · Journal for ImmunoTherapy of Cancer · 3

PDF

718 WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models

2021 · Christopher Nirschl, Heather Brodkin, et al. · Journal for ImmunoTherapy of Cancer · 3

PDF

723 WTX-613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models

2021 · Ethika Tyagi, Heather Brodkin, et al. · Journal for ImmunoTherapy of Cancer · 3

PDF

Abstract 4074: Discovery of WTX-518, an IL-18 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models

2024 · Kristin R. Morris, Heather Brodkin, et al. · Cancer Research · 2

WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike “Non-Alpha” Muteins

2026 · Christopher J. Nirschl, Kulandayan K. Subramanian, et al. · Cancer Immunology Research · 1

T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy

2025 · Megen C. Wittling, Amalia M. Rivera-Reyes, et al. · Cancer Immunology Research · 1

964 Development of conditional T cell engagers (INDUCER™ molecules) with a highly effective masking approach to reduce dose-limiting cytokine release and off-target peripheral toxicity

2025 · Tiziana M Cafarelli, Pamela Aderhold-Camiré, et al. · Journal for ImmunoTherapy of Cancer · 1

PDF

Development of WTX-921, a conditionally activated IL-10 INDUKINETM molecule for the treatment of Inflammatory Bowel Disease 2679

2025 · Jenna M. Sullivan, Pamela A. Aderhold-Camiré, et al. · The Journal of Immunology · 1

PDF

672 The tumor-activated IL-12 prodrug WTX-330 expanded/activated tumor infiltrating lymphocytes and caused tumor regression in patients with refractory solid tumors: interim data from an ongoing Ph1 study

2024 · Devalingam Mahalingam, Mateusz Opyrchal, et al. · Journal for ImmunoTherapy of Cancer · 1

Development of conditionally active IL-10 INDUKINE TM molecules for the treatment of inflammatory bowel disease

2024 · Jenna Sullivan, Pamela Aderhold, et al. · The Journal of Immunology · 1

Abstract 4078: WTX-712, a conditionally active IL-21 INDUKINETM molecule, induces a strong anti-tumor phenotype through a differentiated mechanism

2024 · Jenna M. Sullivan, Pamela A. Aderhold, et al. · Cancer Research · 1

Abstract CT133: Trial in progress: a multicenter phase 1/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors

2023 · Ildefonso Ismael Rodriguez-Rivera, Justin C. Moser, et al. · Cancer Research · 1

Abstract 1829: Generation of IL-21 INDUKINETM molecules for the treatment of cancer

2023 · Jenna M. Sullivan, Pamela A. Aderhold, et al. · Cancer Research · 1

Abstract 2054: WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives anti-tumor immunity by activating tumor infiltrating CD8+ T cells

2022 · Christopher J. Nirschl, Heather R. Brodkin, et al. · Cancer Research · 1

Abstract 1723: WTX-124 is an IL-2 pro-drug conditionally activated in tumors and able to induce complete regressions in mouse tumor models

2021 · Andres Salmeron, Heather Brodkin, et al. · Cancer Research · 1

494 A phase 1b/2 study of the tumor-activated IL-12 prodrug WTX-330 in patients with relapsed/refractory solid tumors

2026 · Justin Moser, Rohan Maniar, et al. · Journal for ImmunoTherapy of Cancer

PDF

1189 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors

2026 · Justin Moser, Hans Hammers, et al. · Journal for ImmunoTherapy of Cancer

PDF

862 Pharmacokinetic insight into the IL-2 INDUKINE prodrug WTX-124: Real-time assessment of tumor-specific activation and immune modulation

2025 · Celesztina Nagy-Domonkos, Heather R Brodkin, et al. · Journal for ImmunoTherapy of Cancer

PDF

Works count: 39

Citation count: 1,636